Physician profile
An-Yu Chen
NPI 1992731269
$25,142.46
in general payments reported to CMS, 2019-2025
49 companies · $5,203 in 2025
The $5,203 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,718 · 2020: $1,934 · 2021: $2,765 · 2022: $4,044 · 2023: $3,168 · 2024: $5,310 · 2025: $5,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,000 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,573.50 |
| Consulting Fee | $1,000.00 |
| Education | $107.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,520.66 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,048.97 | 2019-2025 | Xifaxan, Relistor, Plenvu |
| Janssen Biotech, INC. | $2,253.86 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,629.56 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $1,467.46 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $1,191.35 | 2019-2025 | Livdelzi |
| Pfizer INC. | $889.75 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $700.97 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $699.58 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $537.84 | 2020-2025 | Linzess |
| Genzyme Corporation | $525.17 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $446.27 | 2019-2025 | Rebyota, Cimzia |
| Evoke Pharma, INC. | $420.36 | 2022-2025 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $405.67 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $399.28 | 2024-2025 | Omvoh, Zepbound |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $354.46 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $347.93 | 2019-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $343.33 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $339.52 | 2020-2025 | Ocaliva |
| Celgene Corporation | $335.36 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $242.88 | 2020-2023 | |
| Madrigal Pharmaceuticals | $211.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $208.01 | 2020-2023 | Talicia |
| Janssen Scientific Affairs, LLC | $179.89 | 2019-2022 | |
| Organon LLC | $161.85 | 2023-2025 | Renflexis, Hadlima |
| Novo Nordisk INC | $159.52 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $143.69 | 2025 | Iqirvo, Bylvay |
| Amgen INC. | $142.33 | 2020-2023 | Amjevita, Avsola |
| Romark Laboratories, Lc | $127.26 | 2019-2020 | |
| Celltrion USA INC. | $114.89 | 2024-2025 | Vegzelma, Zymfentra |
| Ucb, INC. | $89.74 | 2019-2020 | |
| Echosens North America, INC. | $61.89 | 2024-2025 | Fibroscan, Fibroscan |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 | |
| Medtronic, INC. | $49.89 | 2021-2023 | Gi Genius |
| Astrazeneca Pharmaceuticals Lp | $48.34 | 2019-2020 | |
| Vivus LLC | $44.98 | 2022-2024 | Qsymia |
| Albireo Pharma, INC. | $42.75 | 2024 | Bylvay, Iqirvo |
| Enterra Medical, INC. | $25.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.59 | 2019 | |
| Digestive Care, INC. | $19.68 | 2023 | Pertzye |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.54 | 2023 | Cyltezo |
| Dynavax Technologies Corporation | $16.75 | 2021 | |
| Daiichi Sankyo INC. | $16.17 | 2019 | |
| Medtronic USA, INC. | $15.95 | 2019 | |
| Aimmune Therapeutics, INC. | $15.09 | 2025 | Zenpep |
| Alfasigma USA, INC. | $14.44 | 2020 | |
| Axonics, INC. | $13.93 | 2022 | |
| Lucid Diagnostics INC. | $13.56 | 2022 | |
| Allergan, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An-Yu Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.